Search results
Results From The WOW.Com Content Network
Shares of the California-based company fell 16% in extended trading. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the ...
(Reuters) -Culper Research has taken a short position on Acadia Pharmaceuticals' stock, it said on Thursday, sending the drugmaker's shares down as much as 8%. Acadia's drug, trofinetide, to treat ...
Total equity. US$699.14 million (2019) Number of employees. 570 (June 30, 2020) Website. acadia .com. Footnotes / references. [1] Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.
ACADIA Pharmaceuticals was on fire yesterday, up 24% after presenting data for its antipsychotic pimavanserin at the American Academy of Neurology annual meeting. The data looked good.
Shares of ACADIA Pharmaceuticals shot through the roof today, up 30% as of this filming. In the video below, Fool health-care analyst David Williamson discusses news of some great phase 3 trial ...
Acadia (ACAD) delivered earnings and revenue surprises of 38.64% and 4.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us